To test this hypothesis, AML cells (THP-1 and U937/MOCK/OE/scramble/shGLI1 cells) were treated with different concentrations of PD 0332991, a CDK4/6 inhibitor, and the viability of these treated cells was determined. The gene discussed is CDK4; the disease is acute myeloid leukemia.